Menu
Search
|

Menu

Close
X

Champions Oncology Inc CSBR.OQ (NASDAQ Stock Exchange Capital Market)

12.99 USD
-0.81 (-5.87%)
As of 2:29 AM IST
chart
Previous Close 13.80
Open 13.86
Volume 28,879
3m Avg Volume 48,555
Today’s High 13.86
Today’s Low 12.40
52 Week High 17.89
52 Week Low 3.15
Shares Outstanding (mil) 11.16
Market Capitalization (mil) 154.07
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY19
6
FY18
20
FY17
15
FY16
11
FY15
9
EPS (USD)
FY19
0.038
FY18
-0.134
FY17
-0.630
FY16
-1.201
FY15
-2.251
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.57
Price to Sales (TTM)
vs sector
7.19
15.43
Price to Book (MRQ)
vs sector
252.80
4.06
Price to Cash Flow (TTM)
vs sector
1,185.15
21.23
Total Debt to Equity (MRQ)
vs sector
47.34
14.84
LT Debt to Equity (MRQ)
vs sector
24.58
11.13
Return on Investment (TTM)
vs sector
-32.77
12.77
Return on Equity (TTM)
vs sector
-71.75
14.47

EXECUTIVE LEADERSHIP

Joel Ackerman
Chairman of the Board, Since 2017
Salary: $11,620.00
Bonus: --
Ronnie Morris
President, Chief Executive Officer, Director, Since 2017
Salary: $15,061.00
Bonus: --
David Miller
Vice President - Finance, Since 2013
Salary: $215,000.00
Bonus: $6,885.00
Philip Breitfeld
Chief Strategic and Innovation Officer, Director, Since 2016
Salary: --
Bonus: --
David Sidransky
Lead Independent Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

855 N Wolfe St Ste 619
BALTIMORE   MD   21205-1511

Phone: +1410.3690365

Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans. The TOS segment provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. Its TumorGraft Technology Platform consists of processes, physical tumors and information that it uses to personalize the development and use of oncology drugs. Each tumor from patients that it has preserved for implantation in mice, along with the patient data and molecular information associated with the tumors, are known as TumorGrafts or Patient Derived XenoGrafts of PDX Models. The collection of TumorGrafts is referred to as the Company's TumorBank.

SPONSORED STORIES